|
|
|
Volumn 22, Issue 11, 2008, Pages 917-
|
|
Raltegravir phase III study data released.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 PYRROLIDONE DERIVATIVE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
BENZOXAZINE DERIVATIVE;
EFAVIRENZ;
INTEGRASE INHIBITOR;
RALTEGRAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
DOUBLE BLIND PROCEDURE;
DRUG COMBINATION;
DRUG EFFECT;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
MULTICENTER STUDY;
NOTE;
PHASE 3 CLINICAL TRIAL;
PHYSIOLOGY;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
VIROLOGY;
VIRUS LOAD;
ANTI-HIV AGENTS;
BENZOXAZINES;
CLINICAL TRIALS, PHASE III AS TOPIC;
DOUBLE-BLIND METHOD;
DRUG THERAPY, COMBINATION;
HIV INFECTIONS;
HIV INTEGRASE INHIBITORS;
HIV-1;
HUMANS;
MULTICENTER STUDIES AS TOPIC;
PYRROLIDINONES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
REVERSE TRANSCRIPTASE INHIBITORS;
TREATMENT OUTCOME;
VIRAL LOAD;
|
|
EID: 58149288669
PISSN: None
EISSN: 15577449
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|